AMUNDSEN - Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI), and randomized to Subcutaneous Evolocumab or Normal strategies to reach guidelines LDL objectives in the real-world - The AMUNDSEN-real trial-

Conditions

acute myocardial infarction

Brief summary

The primary endpoint is a reduction in LDL-C levels ≥ 50% from baseline and an LDL-C level < 1.4 mmol/L at 12 months follow-up., LDL-C levels will be assessed at follow-up visits at 6 and 22 weeks and 12 months after randomisation. (At 38 weeks, 16, 20, 28 and 32 months post-randomisation, only if data are available)., The primary clinical endpoint is the composite endpoint of death (any cause) or any unplanned hospitalization for a CV reason at 12 months

Detailed description

LDL-C<40, mg/dL at 12 months follow-up, Composite of death (any cause), myocardial infarction, stroke, unplanned revascularization at 12 months follow-up, Composite of death (any cause) or myocardial infarction at 12 months follow-up, Death (any cause) at 12 months follow-up, Death (cardiovascular) at 12 months follow-up, Composite of death (any cause), myocardial infarction, stroke at 12 months follow-up

Montalescot G, Bolognese L, Bartus S, Cequier-Fillat A, Thiele H, Mach F, Jukema JW, Ferrari E, Souteyrand G, Bouleti C, Range G, Chioccioli M, Picchi A, Batias-Moreau L, Esposito G, Braik N, Redjimi N, Duband B, Guedeney P, Zeitouni M, Brochard K, Silvain J, Vicaut E, AMUNDSEN investigators of the ACTION Study Group.

2025-11-03

10.1016/j.ahj.2025.107295

Interventions

DRUGRepatha 140 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint is a reduction in LDL-C levels ≥ 50% from baseline and an LDL-C level < 1.4 mmol/L at 12 months follow-up., LDL-C levels will be assessed at follow-up visits at 6 and 22 weeks and 12 months after randomisation. (At 38 weeks, 16, 20, 28 and 32 months post-randomisation, only if data are available)., The primary clinical endpoint is the composite endpoint of death (any cause) or any unplanned hospitalization for a CV reason at 12 months	—

Measure

Time frame

The primary endpoint is a reduction in LDL-C levels ≥ 50% from baseline and an LDL-C level < 1.4 mmol/L at 12 months follow-up., LDL-C levels will be assessed at follow-up visits at 6 and 22 weeks and 12 months after randomisation. (At 38 weeks, 16, 20, 28 and 32 months post-randomisation, only if data are available)., The primary clinical endpoint is the composite endpoint of death (any cause) or any unplanned hospitalization for a CV reason at 12 months

—

Secondary

Measure	Time frame
LDL-C<40, mg/dL at 12 months follow-up, Composite of death (any cause), myocardial infarction, stroke, unplanned revascularization at 12 months follow-up, Composite of death (any cause) or myocardial infarction at 12 months follow-up, Death (any cause) at 12 months follow-up, Death (cardiovascular) at 12 months follow-up, Composite of death (any cause), myocardial infarction, stroke at 12 months follow-up	—